Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models

[61] Luedde T(2019)Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population Biol Blood Marrow Transplant 25 2091-920

[62] van Dam R(2020)Antimicrobial de-escalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of unknown origin J Oncol Pharm Pract 26 632-598

[63] Lang SA(2017)Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy Support Care Cancer 25 3715-2542

[64] Gianotti L(2019)Risk, Outcomes, and Trends of Clostridium Difficile Infection in Multiple Myeloma Patients from a Nationwide Analysis Cureus 11 e4391-9

[65] Tamini N(2017)Risk factors and impact of Clostridium difficile recurrence on haematology patients J Antimicrob Chemother 72 1488-3242

[66] Gavazzi F(2020)Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome Bone Marrow Transplant 55 367-1081

[67] Mariani A(2018)Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study South Med J 111 628-e1818

[68] Sandini M(2015)Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis Infect Control Hosp Epidemiol 36 794-225

[69] Ferla F(2016)Clostridium difficile infections amongst patients with haematological malignancies: a data linkage study PloS One 11 e0157839-2368

[70] Lee D-S(2019)Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study Leuk Lymphoma 60 2787-1107

[61] Luedde T(2019)Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population Biol Blood Marrow Transplant 25 2091-920

[62] van Dam R(2020)Antimicrobial de-escalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of unknown origin J Oncol Pharm Pract 26 632-598

[63] Lang SA(2017)Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy Support Care Cancer 25 3715-2542

[64] Gianotti L(2019)Risk, Outcomes, and Trends of Clostridium Difficile Infection in Multiple Myeloma Patients from a Nationwide Analysis Cureus 11 e4391-9

[65] Tamini N(2017)Risk factors and impact of Clostridium difficile recurrence on haematology patients J Antimicrob Chemother 72 1488-3242

[66] Gavazzi F(2020)Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome Bone Marrow Transplant 55 367-1081

[67] Mariani A(2018)Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study South Med J 111 628-e1818

[68] Sandini M(2015)Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis Infect Control Hosp Epidemiol 36 794-225

[69] Ferla F(2016)Clostridium difficile infections amongst patients with haematological malignancies: a data linkage study PloS One 11 e0157839-2368

[70] Lee D-S(2019)Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study Leuk Lymphoma 60 2787-1107